GlaxoSmithKline receives EU approval for COPD therapy Trelegy Ellipta

GlaxoSmithKline has announced that its chronic obstructive pulmonary disease (COPD) therapy Trelegy Ellipta has been approved by the European Commission.

EU regulators have granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe COPD who have not been adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

Trelegy Ellipta is the first once-daily single-inhaler triple therapy to be approved in Europe, and combines an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta 2-adrenergic agonist, delivered once daily using the Ellipta dry powder inhaler.

It has demonstrated efficacy and safety in phase III trials, and is expected to make its European commercial debut before the end of the year, having also recently been approved in the US.

Eric Dube, senior vice-president and head of GlaxoSmithKline's global respiratory franchise, said: "We believe this is an important innovation in COPD management and look forward to making it available for appropriate patients with COPD."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.